Related Experiment Videos
R Cohen1, M Tauzin2, S Béchet3
1ACTIV, Association Clinique et Thérapeutique Infantile du Val de Marne, 27 Rue Inkermann, Saint-Maur des Fossés, France; üniversité Paris Est, IMRB-GRC GEMINI, 40 Avenue de Verdun 94000 Créteil, France; Centre de Recherche Clinique (CRC), Centre Hospitalier Intercommunal de Créteil, 40 Avenue de Verdun 94000 Créteil, France; Groupe de Pathologie Infectieuse Pédiatrique (GPIP), 27 Rue Inkermann, Saint-Maur des Fossés, France; ünité Court Séjour, Petits Nourrissons, Service de Néonatologie, Centre Hospitalier Intercommunal de Créteil, 40 Avenue de Verdun 94000 Créteil, France.
Optimizing antibiotic use in neonates requires understanding pharmacokinetic and pharmacodynamic (PK/PD) variability. This review details PK/PD data for key neonatal antibiotics to improve treatment efficacy and safety.
Area of Science:
- Pharmacology
- Neonatology
- Infectious Diseases
Context:
- Neonates display significant inter-individual variability in antibiotic levels due to physiological immaturity and rapid developmental changes.
- This variability necessitates wider therapeutic margins to ensure effective antibiotic treatment in neonates.
- Neonatal sepsis management requires consideration of antibiotic pharmacokinetic and pharmacodynamic properties, including minimal inhibitory concentrations against common pathogens like group B Streptococcus and Escherichia coli.
Purpose:
- To present pharmacokinetic and pharmacodynamic (PK/PD) data for antimicrobial agents commonly used in neonatal care.
- To aid clinicians in rationalizing antibiotic selection and dosing strategies for neonates.
- To improve the understanding of antibiotic behavior in the unique physiological environment of newborns.
Summary:
- This paper reviews the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of essential antimicrobial agents, specifically ß-lactams and aminoglycosides, frequently prescribed for neonatal infections.
- It highlights the substantial inter-individual variability in drug levels observed in neonates, stemming from developmental immaturities.
- The review emphasizes the importance of integrating PK/PD targets, such as minimal inhibitory concentration (MIC), with clinical data for optimizing treatment of neonatal sepsis.
Impact:
- Provides clinicians with crucial PK/PD data to guide evidence-based antibiotic therapy in neonates.
- Aims to enhance therapeutic outcomes and minimize adverse events associated with antibiotic use in this vulnerable population.
- Contributes to the development of more precise and individualized antibiotic dosing regimens for neonatal infections.